



501-3292 Production Way, Burnaby, B.C., V5A 4R4

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Improves Performance of FAIMS Marijuana Breathalyzer – CNN Coverage

Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety

Vancouver, British Columbia, January 7, 2020 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace, reports that engineers have developed and deployed new ion optics methods that have resulted in a 6 times increase in analyte signal which has increased the sensitivity in the Company’s FAIMS (field asymmetric waveform ion mobility spectrometry) $\Delta 9$ -tetrahydrocannabinol (“THC”) detection device. The Company has been working for the last several months on improving “ion optics” which is a critical component of the FAIMS system in order to better focus and maximize ion flow through the FAIMS cell “keyhole”. Members of Cannabix advisory team, including Dr. Yost and Dr. Purves were instrumental in providing guidance on the latest technological enhancements leading to this improvement. Furthermore, the Company reports that Cannabix scientists have been testing with a single stage, direct breath with the FAIMS device, that allows for real-time collection and analysis of low volatility compounds without sample preparation.

In addition, Company engineers have been pushing forward development of its THC Breath Analyzer (“THCBA”) which incorporates microfluidic sensor technology for the detection of $\Delta 9$ -tetrahydrocannabinol (“THC”) from breath. As announced in November, engineers have reduced the size of several components inside the THCBA for a more compact device, over the course of December, engineers have been further optimizing breath sample chamber design and tested additional sensors that work in conjunction with microfluidic sensor. Furthermore, the form factor (exterior) design of the THCBA will see additional refinements in due course.

The Company reports that it has received notable media coverage from CNN in an article titled, “Testing drivers for cannabis is hard. Here’s why” published recently in CNN Business. The article makes mention of Cannabix Technologies’ development work with its marijuana breathalyzer technologies. The full article can be viewed at: <https://www.cnn.com/2020/01/02/business/cannabis-breathalyzers-are-coming-to-market/index.html>

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in

contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.